Further Positive Preclinical Results for ARG-007 In HIE
Filed with ASX · · 5 pages · English
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- Argenica Receives Ethics Approval To Commence Phase 1 Trial
- Appendix 4E & Annual Report 30 June 2022
- Peer Reviewed Paper Published on Preclinical Safety Study
- Application for quotation of securities - AGN
- Argenica Successfully Completes $5.5m Placement
Later from Argenica Therapeutics
- Argenica Receives $1.38m R&D Tax Incentive Cash Refund
- First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007
- No Serious Safety Issues Observed in First Cohort
- Safety Review Committee Approves Second Cohort
- Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics